[Effect of combined therapy with securinine and stanozolol in patients with chronic aplastic anemia].
D000293:Adolescent; D000328:Adult; D000470:Alkaloids / Q000008:administration & dosage* / Q000009:adverse effects; D000741:Anemia, Aplastic / Q000188:drug therapy*; D001381:Azepines; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006576:Heterocyclic Compounds, 4 or More Rings; D006572:Heterocyclic Compounds, Bridged-Ring; D006801:Humans; D007783:Lactones; D008297:Male; D008875:Middle Aged; D010880:Piperidines; D013197:Stanozolol / Q000008:administration & dosage* / Q000009:adverse effects
D000470:Alkaloids; D001381:Azepines; D000697:Central Nervous System Stimulants; D006576:Heterocyclic Compounds, 4 or More Rings; D006572:Heterocyclic Compounds, Bridged-Ring; D007783:Lactones; D010880:Piperidines; D013197:Stanozolol; C000785:securinine